Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. Holden Karnofsky is a co-founder and the former CEO of Open Philanthropy. He left Open Philanthropy in April 2024. We believe that every life has equal...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. Open Philanthropy is interested in when AI systems will be able to perform various tasks that humans can perform (“AI timelines”). To inform our thinking, I investigated what...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. Holden Karnofsky is a co-founder and the former CEO of Open Philanthropy. He left Open Philanthropy in April 2024. This post compares our progress with the...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. As part of our work on biosecurity and pandemic preparedness, we have contracted Good Judgment Inc. to expand its efforts to aggregate, publish, and track forecasts...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. Holden Karnofsky is a co-founder and the former CEO of Open Philanthropy. He left Open Philanthropy in April 2024. We believe that every life has equal value — and that...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. How accurate do long-range (≥10yr) forecasts tend to be, and how much should we rely on them? As an initial exploration of this question, I sought...
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. Although we have typically emphasized the importance for effective philanthropy of long-term commitment to causes and getting the right people in place, the most obvious day-to-day...
Our thinking on prioritizing across different causes has evolved as we’ve made more grants. This post explores one aspect of that: the high bar set by the best global health and development interventions, and what we’re learning about the relative performance of some of our other grantmaking areas that seek to help people today.
In 2019, we awarded a five-year grant and made an additional investment in Sherlock Biosciences to support the development of a diagnostic platform to quickly, easily, and inexpensively identify any human virus present in a patient sample.
Editor’s note: This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing here. In 2016, we (Open Philanthropy) published two blog posts (1, 2) to explain why our grantmaking focus area related to AI is narrowly focused on funding...
